Elevated Plasma Levels of sCD14 and MCP-1 Are Associated With HIV Associated Neurocognitive Disorders Among Antiretroviral-Naive Individuals in Nigeria.
Journal
Journal of acquired immune deficiency syndromes (1999)
ISSN: 1944-7884
Titre abrégé: J Acquir Immune Defic Syndr
Pays: United States
ID NLM: 100892005
Informations de publication
Date de publication:
01 06 2020
01 06 2020
Historique:
pubmed:
23
2
2020
medline:
7
1
2021
entrez:
22
2
2020
Statut:
ppublish
Résumé
Mononuclear cells play key roles in the pathogenesis of HIV-associated neurocognitive disorders (HAND). Limited studies have looked at the association of markers of monocyte activation with HAND in Africa. We examined this association among HIV-1-infected patients in Nigeria. A total of 190 HIV-infected treatment-naive participants with immune marker data were included in this cross-sectional study. Plasma levels of soluble CD14 (sCD14), soluble CD163, monocyte chemoattractant protein-1 (MCP-1), tumor necrosis factor-alpha (TNF-α), and neopterin were measured. Demographically adjusted T scores obtained from a 7-domain neuropsychological test battery were generated, and functional status was assessed using activities of daily living questionnaire. Participants were classified as unimpaired, having asymptomatic neurocognitive impairment (ANI), mild neurocognitive disorder (MND), or HIV-associated dementia (HAD) in line with the "Frascati" criteria. Thirty-two participants (16.8%) had ANI, 14 (7.4%) had MND, whereas none had HAD. In multivariable linear regression analyses, after adjusting for age, gender, education, CD4 count, and viral load, mean levels of sCD14 were higher among those with ANI and MND as compared with the unimpaired (P = 0.033 and 0.023, respectively). Similarly, the mean level of MCP-1 was greater among those with HAND as compared with the unimpaired (P = 0.047). There were also trends for higher levels of sCD163 and TNF-α among females with MND in univariable analyses. Levels of monocyte activation markers correlate with the severity of impairment among individuals with HAND. The mechanisms that underlie these effects and the potential role of gender require further study.
Sections du résumé
BACKGROUND
Mononuclear cells play key roles in the pathogenesis of HIV-associated neurocognitive disorders (HAND). Limited studies have looked at the association of markers of monocyte activation with HAND in Africa. We examined this association among HIV-1-infected patients in Nigeria.
METHOD
A total of 190 HIV-infected treatment-naive participants with immune marker data were included in this cross-sectional study. Plasma levels of soluble CD14 (sCD14), soluble CD163, monocyte chemoattractant protein-1 (MCP-1), tumor necrosis factor-alpha (TNF-α), and neopterin were measured. Demographically adjusted T scores obtained from a 7-domain neuropsychological test battery were generated, and functional status was assessed using activities of daily living questionnaire. Participants were classified as unimpaired, having asymptomatic neurocognitive impairment (ANI), mild neurocognitive disorder (MND), or HIV-associated dementia (HAD) in line with the "Frascati" criteria.
RESULTS
Thirty-two participants (16.8%) had ANI, 14 (7.4%) had MND, whereas none had HAD. In multivariable linear regression analyses, after adjusting for age, gender, education, CD4 count, and viral load, mean levels of sCD14 were higher among those with ANI and MND as compared with the unimpaired (P = 0.033 and 0.023, respectively). Similarly, the mean level of MCP-1 was greater among those with HAND as compared with the unimpaired (P = 0.047). There were also trends for higher levels of sCD163 and TNF-α among females with MND in univariable analyses.
CONCLUSIONS
Levels of monocyte activation markers correlate with the severity of impairment among individuals with HAND. The mechanisms that underlie these effects and the potential role of gender require further study.
Identifiants
pubmed: 32084055
doi: 10.1097/QAI.0000000000002320
pii: 00126334-202006010-00009
doi:
Substances chimiques
Anti-Retroviral Agents
0
CCL2 protein, human
0
Chemokine CCL2
0
Lipopolysaccharide Receptors
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
196-202Subventions
Organisme : BLRD VA
ID : I01 BX003222
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA044908
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH086356
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW001041
Pays : United States
Références
Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853–860.
Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA. 1998;280:1497–1503.
Dore GJ, McDonald A, Li Y, et al. Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS. 2003;17:1539–1545.
Heaton RK, Clifford DB, Franklin DR Jr, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010;75:2087–2096.
Habib AG, Yakasai AM, Owolabi LF, et al. Neurocognitive impairment in HIV-1-infected adults in Sub-Saharan Africa: a systematic review and meta-analysis. Int J Infect Dis. 2013;17:e820–e831.
Nightingale S, Winston A, Letendre S, et al. Controversies in HIV-associated neurocognitive disorders. Lancet Neurol. 2014;13:1139–1151.
Burdo TH, Lackner A, Williams KC. Monocyte/macrophages and their role in HIV neuropathogenesis. Immunological Rev. 2013;254:102–113.
Smurzynski M, Wu K, Letendre S, et al. Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS. 2011;25:357–365.
Ancuta P, Kamat A, Kunstman KJ, et al. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One. 2008;3:e2516.
Gannon P, Khan MZ, Kolson DL. Current understanding of HIV-associated neurocognitive disorders pathogenesis. Curr Opin Neurol. 2011;24:275–283.
Gonzalez-Scarano F, Martin-Garcia J. The neuropathogenesis of AIDS. Nat Rev Immunol. 2005;5:69–81.
Rao VR, Ruiz AP, Prasad VR. Viral and cellular factors underlying neuropathogenesis in HIV associated neurocognitive disorders (HAND). AIDS Res Ther. 2014;11:13.
Lyons JL, Uno H, Ancuta P, et al. Plasma sCD14 is a biomarker associated with impaired neurocognitive test performance in attention and learning domains in HIV infection. J Acquir Immune Defic Syndr. 2011;57:371–379.
Conant K, Garzino-Demo A, Nath A, et al. Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia. Proc Natl Acad Sci U S A. 1998;95:3117–3121.
Spudich SS, Ances BM. Neurologic complications of HIV infection: highlights from the 2013 conference on retroviruses and opportunistic infections. Top Antivir Med. 2013;21:100–108.
Burdo TH, Weiffenbach A, Woods SP, et al. Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection. AIDS. 2013;27:1387–1395.
Royal W III, Cherner M, Burdo TH, et al. Associations between cognition, gender and monocyte activation among HIV infected individuals in Nigeria. PLoS One. 2016;11:e0147182.
Buch S, Chivero ET, Hoare J, et al. Proceedings from the NIMH symposium on NeuroAIDS in Africa: neurological and neuropsychiatric complications of HIV. J Neurovirol. 2016;22:699–702.
Jumare J, Sunshine S, Ahmed H, et al. Peripheral blood lymphocyte HIV DNA levels correlate with HIV associated neurocognitive disorders in Nigeria. J Neurovirol. 2017;23:474–482.
Jumare J, Ndembi N, El-Kamary SS, et al. Cognitive function among antiretroviral treatment–naive individuals infected with human immunodeficiency virus type 1 subtype G versus CRF02_AG in Nigeria. Clin Infect Dis. 2017;66:1448–1453.
Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory-II. 1. San Antonio, TX: Psychological Corporation; 1996:82.
Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69:1789–1799.
Jumare J, El-Kamary SS, Magder L, et al. Plasma HIV RNA level is associated with neurocognitive function among HIV-1-infected patients in Nigeria. J Neurovirol. 2018;24:712–719.
Ryan LA, Zheng J, Brester M, et al. Plasma levels of soluble CD14 and tumor necrosis factor-alpha type II receptor correlate with cognitive dysfunction during human immunodeficiency virus type 1 infection. J Infect Dis. 2001;184:699–706.
Marcotte TD, Deutsch R, Michael BD, et al. A concise panel of biomarkers identifies neurocognitive functioning changes in HIV-infected individuals. J Neuroimmune Pharmacol. 2013;8:1123–1135.
McGuire JL, Gill AJ, Douglas SD, et al. Central and peripheral markers of neurodegeneration and monocyte activation in HIV-associated neurocognitive disorders. J Neurovirol. 2015;21:439–448.
Cinque P, Vago L, Mengozzi M, et al. Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication. AIDS. 1998;12:1327–1332.
Monteiro de Almeida S, Letendre S, Zimmerman J, et al. Dynamics of monocyte chemoattractant protein type one (MCP-1) and HIV viral load in human cerebrospinal fluid and plasma. J Neuroimmunol. 2005;169:144–152.
Sevigny JJ, Albert SM, McDermott MP, et al. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology. 2004;63:2084–2090.
Hagberg L, Cinque P, Gisslen M, et al. Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res Ther. 2010;7:1742–6405.
World Health Organization. Progress report 2016: prevent HIV, test and treat all: WHO support for country impact. Available at: https://apps.who.int/iris/bitstream/handle/10665/251713/WHO-HIV-2016.24-eng.pdf?sequence=1&isAllowed=y. Accessed November 2019.
Gendelman HE, Zheng J, Coulter CL, et al. Suppression of inflammatory neurotoxins by highly active antiretroviral therapy in human immunodeficiency virus-associated dementia. J Infect Dis. 1998;178:1000–1007.
Wesselingh SL, Power C, Glass JD, et al. Intracerebral cytokine messenger RNA expression in acquired immunodeficiency syndrome dementia. Ann Neurol. 1993;33:576–582.
Kamat A, Lyons JL, Misra V, et al. Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection. J Acquir Immune Defic Syndr. 2012;60:234–243.
Addo MM, Altfeld M. Sex-based differences in HIV type 1 pathogenesis. J Infect Dis. 2014;209(suppl 3):S86–S92.
Hearps AC, Martin GE, Angelovich TA, et al. Aging is associated with chronic innate immune activation and dysregulation of monocyte phenotype and function. Aging Cell 2012;11:867–875.
Carrico AW, Johnson MO, Morin SF, et al. Stimulant use is associated with immune activation and depleted tryptophan among HIV-positive persons on anti-retroviral therapy. Brain Behav Immun. 2008;22:1257–1262.
Gonzalez VD, Landay AL, Sandberg JK. Innate immunity and chronic immune activation in HCV/HIV-1 co-infection. Clin Immunol. 2010;135:12–25.
Gartner S, Liu Y. Insights into the role of immune activation in HIV neuropathogenesis. J Neurovirol. 2002;8:69–75.
Zhu T. HIV-1 in peripheral blood monocytes: an underrated viral source. J Antimicrob Chemother. 2002;50:309–311.
Gibellini D, Borderi M, De Crignis E, et al. HIV-1 DNA load analysis in peripheral blood lymphocytes and monocytes from naive and HAART-treated individuals. J Infect. 2008;56:219–225.
Price RW, Brew B, Sidtis J, et al. The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex. Science. 1988;239:586–592.
Glass JD, Fedor H, Wesselingh SL, et al. Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Ann Neurol. 1995;38:755–762.
Eugenin EA, Osiecki K, Lopez L, et al. CCL2/monocyte chemoattractant protein-1 mediates enhanced transmigration of human immunodeficiency virus (HIV)-infected leukocytes across the blood-brain barrier: a potential mechanism of HIV-CNS invasion and NeuroAIDS. J Neurosci. 2006;26:1098–1106.
Dhillon NK, Williams R, Callen S, et al. Roles of MCP-1 in development of HIV-dementia. Front Biosci. 2008;13:3913–3918.
Shive CL, Jiang W, Anthony DD, et al. Soluble CD14 is a nonspecific marker of monocyte activation. AIDS (London, England). 2015;29:1263–1265.
Redd AD, Dabitao D, Bream JH, et al. Microbial translocation, the innate cytokine response, and HIV-1 disease progression in Africa. Proc Natl Acad Sci. 2009;106:6718–6723.
Lien E, Aukrust P, Sundan A, et al. Elevated levels of serum-soluble CD14 in human immunodeficiency virus type 1 (HIV-1) infection: correlation to disease progression and clinical events. Blood. 1998;92:2084–2092.
Grunwald U, Fan X, Jack RS, et al. Monocytes can phagocytose Gram-negative bacteria by a CD14-dependent mechanism. J Immunol. 1996;157:4119–4125.
Landmann R, Link S, Sansano S, et al. Soluble CD14 activates monocytic cells independently of lipopolysaccharide. Infect Immun. 1998;66:2264–2271.
Haziot A, Ferrero E, Kontgen F, et al. Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice. Immunity. 1996;4:407–414.
Hatano H. Immune activation and HIV persistence: considerations for novel therapeutic interventions. Curr Opin HIV AIDS. 2013;8:211–216.
Lawn SD, Butera ST, Folks TM. Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection. Clin Microbiol Rev. 2001;14:753–777.
Rizzardini G, Piconi S, Ruzzante S, et al. Immunological activation markers in the serum of African and European HIV-seropositive and seronegative individuals. AIDS. 1996;10:1535–1542.
Rizzardini G, Trabattoni D, Saresella M, et al. Immune activation in HIV-infected African individuals. Italian-Ugandan AIDS cooperation program. AIDS. 1998;12:2387–2396.
Toossi Z, Funderburg NT, Sirdeshmuk S, et al. Systemic immune activation and microbial translocation in dual HIV/tuberculosis-infected subjects. J Infect Dis. 2013;207:1841–1849.
Lin Y, Gong J, Zhang M, et al. Production of monocyte chemoattractant protein 1 in tuberculosis patients. Infect Immun. 1998;66:2319–2322.
Wenisch C, Wenisch H, Parschalk B, et al. Elevated levels of soluble CD14 in serum of patients with acute Plasmodium falciparum malaria. Clin Exp Immunol. 1996;105:74–78.
Kaul M, Garden GA, Lipton SA. Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature. 2001;410:988–994.